In a report issued on March 1, Chris Shibutani from Cowen & Co. maintained a Buy rating on Nektar Therapeutics (NKTR), with a price target of $86. The company’s shares closed yesterday at $38.40, close to its 52-week low of $29.22.
According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 4.7% and a 47.6% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Five Prime Therapeutics, United Therapeutics, and Mirati Therapeutics.
Currently, the analyst consensus on Nektar Therapeutics is a Strong Buy with an average price target of $78.86, a 105.4% upside from current levels. In a report issued on February 21, BMO Capital also initiated coverage with a Buy rating on the stock with a $75 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $111.36 and a one-year low of $29.22. Currently, Nektar Therapeutics has an average volume of 1.97M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms. It operates through the United States and Europe geogrpahical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.
